Integrated n-and o-glycomics of acute myeloid leukemia (Aml) cell lines

Abstract

Acute myeloid leukemia (AML) is characterized by a dysregulated expansion of poorly differentiated myeloid cells. Although patients are usually treated effectively by chemotherapy, a high rate of relapsed or refractory disease poses a major hurdle in its treatment. Recently, several studies have proposed implications of protein glycosylation in the pathobiology of AML including chemoresistance. Accordingly, associations have been found between specific glycan epitopes and the outcome of the disease. To advance this poorly studied field, we performed an exploratory gly-comics study characterizing 21 widely used AML cell lines. Exploiting the benefits of porous graph-itized carbon chromatography coupled to tandem mass spectrometry (PGC nano-LC-MS2), we qual-itatively and quantitatively profiled N-and O-linked glycans. AML cell lines exhibited distinct glycan fingerprints differing in relevant glycan traits correlating with their cellular phenotype as clas-sified by the FAB system. By implementing transcriptomics data, specific glycosyltransferases and hematopoietic transcription factors were identified, which are candidate drivers of the glycan phenotype of these cells. In conclusion, we report the varying expression of glycan structures across a high number of AML cell lines, including those associated with poor prognosis, identified underly-ing glycosyltransferases and transcription factors, and provide insights into the regulation of the AML glycan repertoire.